Skip to main content
Clinical Trials/NCT02412618
NCT02412618
Completed
Phase 4

A Randomized Comparison of Same-Day Oral Mifepristone-Misoprostol to Misoprostol Only for Cervical Preparation in Second Trimester Surgical Abortion

Medstar Health Research Institute0 sites100 target enrollmentSeptember 2012

Overview

Phase
Phase 4
Intervention
Mifepristone
Conditions
Induced Abortion
Sponsor
Medstar Health Research Institute
Enrollment
100
Primary Endpoint
Initial Cervical Dilation
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

A randomized double---blinded comparison of same---day mifepristone and misoprostol with misoprostol only for cervical preparation in second---trimester surgical abortion in 100 women at 14 0/7---19 6/7 weeks gestation.

Detailed Description

Women desiring abortion at gestational ages between 14 weeks 0 days and 19 weeks 6 days were randomized to 200-mg mifepristone or identical placebo with 400-mcg misoprostol vaginally 4-6 hours prior to D\&E. Primary outcome was cervical dilation assessed by the largest Hegar dilator accepted without resistance. Secondary outcomes included total procedure time, and patient and provider perceptions. The study was powered to detect a 2-mm difference in cervical dilatation with 48 participants in each arm.

Registry
clinicaltrials.gov
Start Date
September 2012
End Date
January 2014
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Medstar Health Research Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • healthy women
  • eligible for non---urgent D\&E
  • 14 0/7 weeks to 19 6/7 weeks gestation, confirmed by sonogram

Exclusion Criteria

  • emergent need for D\&E
  • fetal demise
  • intolerance
  • allergy or contraindication to mifepristone or misoprostol

Arms & Interventions

Mifepristone

Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once

Intervention: Mifepristone

Mifepristone

Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once

Intervention: Misoprostol

Placebo

Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once

Intervention: Misoprostol

Placebo

Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once

Intervention: Placebo

Outcomes

Primary Outcomes

Initial Cervical Dilation

Time Frame: Assessed 4-6 hour following medications at time of D&E procedure

Initial cervical dilation as measured by Hegar Dilator accepted with least resistance

Secondary Outcomes

  • Patient Acceptability and Assessment of Pain and Side Effects (5-point Likert Scale)(intraoperative)

Similar Trials